<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ddr21709-tbl-0003" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
 <label>TABLE 3</label>
 <caption>
  <p>Therapeutics intervening viral replication process</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="bottom" rowspan="1" colspan="1">Target</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Specific effect/target molecule</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Intervention(s)</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Status of SARS‐CoV‐2 trial</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Sponsor/collaborators</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">NCT number</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td rowspan="7" align="left" valign="top" colspan="1">Protease</td>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 ASC09/ritonavir</p>
     <p>†2 lopinavir/ritonavir</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Not applicable</td>
    <td align="left" valign="top" rowspan="1" colspan="1">First Affiliated Hospital of Zhejiang University, Ascletis Pharmaceuticals Co., Ltd.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04261907</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 ASC09F + Oseltamivir</p>
     <p>†2 Ritonavir + Oseltamivir</p>
     <p>†3 Oseltamivir</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Tongji Hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04261270</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Darunavir and Cobicistat</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Shanghai Public Health Clinical Center</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04252274</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Ganovo + ritonavir ± interferon nebulization</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 4</td>
    <td align="left" valign="top" rowspan="1" colspan="1">The Ninth Hospital of Nanchang, Ascletis Pharmaceuticals Co., Ltd.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04291729</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Lopinavir/ritonavir</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Darrell Tan, St. Michael's Hospital, Toronto; Jiangxi Qingfeng Pharmaceutical Co. Ltd.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04321174, NCT04295551</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Lopinavir/ritonavir</p>
     <p>†2 Hydroxychloroquine sulfate</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Asan Medical Center</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04307693</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">3CLpro</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Lopinavir/ritonavir</p>
     <p>†2 Hydroxychloroquine sulfate</p>
     <p>†3 Baricitinib (Janus kinase inhibitor)</p>
     <p>†4 Sarilumab (anti‐IL‐6 receptor)</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Lisa Barrett, Nova Scotia Health Authority, Dalhousie University</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04321993</td>
   </tr>
   <tr>
    <td rowspan="3" align="left" valign="top" colspan="1">RdRp</td>
    <td align="left" valign="top" rowspan="1" colspan="1">RdRp</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Favipiravir combined with Tocilizumab</p>
     <p>†2 Favipiravir</p>
     <p>†3 Tocilizumab</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Not applicable</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Peking University First Hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04310228</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">RdRp</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Remdesivir</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Gilead Sciences; U.S. Army Medical Research and Development Command; Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France; Capital Medical University, Chinese Academy of Medical Sciences; Capital Medical University; Gilead Sciences; National Institute of Allergy and Infectious Diseases (NIAID)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04323761, NCT04302766, NCT04315948, NCT04252664, NCT04257656, NCT04292899, NCT04292730, NCT04280705</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">RdRp</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Ribavirin</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Not applicable</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Jiangsu Famous Medical Technology Co., Ltd.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04306497</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">RdRp</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Galidesivir (BCX4430)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td>
    <td align="left" valign="top" rowspan="1" colspan="1">BioCryst Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT03891420</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"/>
    <td align="left" valign="top" rowspan="1" colspan="1">RdRp</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Triazavirin</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Health Commission of Heilongjiang province</td>
    <td align="left" valign="top" rowspan="1" colspan="1">ChiCTR2000030001</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="ddr21709-ntgp-0003">
  <fn id="ddr21709-note-0003">
   <p>
    <italic>Note:</italic> †1, †2, †3, and †4 are different arms of parallel intervention.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
